Fate Therapeutics Inc Cash Flow Conversion Efficiency
Fate Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Fate Therapeutics Inc (FATE) has a cash flow conversion efficiency ratio of -0.104x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.37 Million) by net assets ($234.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fate Therapeutics Inc (2011–2024)
Cash flow conversion efficiency of Fate Therapeutics Inc from 2011 to 2024. This chart illustrates how Fate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View FATE stock price and chart for real-time trading data and today's change.
Fate Therapeutics Inc Cash Flow Conversion Ratio Explained
Fate Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fate Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market value of Fate Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KANGWON Co. Ltd
KQ:114190
|
0.077x |
|
Bastas Baskent Cimento Sanayi ve Ticaret AS
IS:BASCM
|
0.160x |
|
Informa PLC
LSE:INF
|
0.044x |
|
Diamond Building Products Public Company Limited
BK:DRT
|
0.054x |
|
Lastminute.com NV
F:09B
|
-0.327x |
|
SKM Egg Products Export (India) Limited
NSE:SKMEGGPROD
|
-0.028x |
|
Valiant Organics Limited
NSE:VALIANTORG
|
0.121x |
|
Lara Exploration Ltd.
V:LRA
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Fate Therapeutics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Fate Therapeutics Inc from 2011 to 2024. Review FATE cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $318.73 Million | $-122.87 Million | -0.386x | -7.39% |
| 2023-12-31 | $368.42 Million | $-132.26 Million | -0.359x | +30.00% |
| 2022-12-31 | $483.94 Million | $-248.21 Million | -0.513x | -113.77% |
| 2021-12-31 | $678.84 Million | $-162.87 Million | -0.240x | -135.13% |
| 2020-12-31 | $384.44 Million | $-39.23 Million | -0.102x | +69.97% |
| 2019-12-31 | $244.76 Million | $-83.17 Million | -0.340x | -41.09% |
| 2018-12-31 | $160.47 Million | $-38.65 Million | -0.241x | +49.62% |
| 2017-12-31 | $77.19 Million | $-36.91 Million | -0.478x | -17.28% |
| 2016-12-31 | $73.15 Million | $-29.82 Million | -0.408x | +15.71% |
| 2015-12-31 | $38.04 Million | $-18.40 Million | -0.484x | +38.86% |
| 2014-12-31 | $28.34 Million | $-22.42 Million | -0.791x | -161.66% |
| 2013-12-31 | $50.85 Million | $-15.37 Million | -0.302x | -220.32% |
| 2012-12-31 | $-52.83 Million | $-13.27 Million | 0.251x | +4.86% |
| 2011-12-31 | $-50.68 Million | $-12.14 Million | 0.240x | -- |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more